Evidence map›Paper›PMID 38388535›Full record

ArticleScientific reports2024

Increased monocytic myeloid-derived suppressor cells in type 2 diabetes correlate with hyperglycemic and was a risk factor of infection and tumor occurrence.

Ji Zhou, Mengjie Zhang, Xiaodi Ju, Huiping Wang, Hao Xiao, Zhimin Zhai, Xing Zhong, Jingfang Hong

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ji ZhouDepartment of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, 230032, Anhui, China.
Mengjie ZhangDepartment of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230601, Anhui, China.
Xiaodi JuSchool of Nursing, Anhui Medical University, Hefei, 230032, Anhui, China.
Huiping WangHematologic Department/Hematologic Disease Research Center, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Hao XiaoHematologic Department/Hematologic Disease Research Center, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Zhimin ZhaiHematologic Department/Hematologic Disease Research Center, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Xing ZhongDepartment of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230601, Anhui, China. zhongxing761@163.com.
Jingfang HongSchool of Nursing, Anhui Medical University, Hefei, 230032, Anhui, China. 13739273006@163.com.

Funding

National Natural Science Foundation of China [grant number. 81573017]
6 · The paper itself

Abstract

To investigate the frequency of monocytic myeloid-derived suppressor cells (M-MDSCs) in type 2 diabetes mellitus (T2DM) patients and explore the potential associations between M-MDSCs, glycemic control, and the occurrence of infections and tumor. 102 healthy and 77 T2DM individuals were enrolled. We assessed the M-MDSCs frequency, levels of fasting plasma glucose (FPG), haemoglobin A1c (HbA1c), and other relevant indicators. Each patient underwent a follow-up of at least 6 months after M-MDSCs detection. The M-MDSCs frequency was significantly higher in patients with poor glycemic control (PGC) compared to the healthy population (P < 0.001), whereas there was no significant difference between patients with good glycemic control and the healthy (P > 0.05). There was a positive correlation between the M-MDSCs frequency and FPG, HbA1c (R = 0.517 and 0.315, P < 0.001, respectively). T2DM patients with abnormally increased M-MDSCs have a higher incidence of infection and tumor (48.57% and 11.43% respectively). Our results shed new light on the pathogenesis of T2DM, help to understand why T2DM patients are susceptible to infection and tumor and providing novel insights for future prevention and treatment of T2DM.

Indexed as

Diabetes Mellitus, Type 2Myeloid-Derived Suppressor CellsNeoplasmsGlycated HemoglobinHumansRisk FactorsGlycated Hemoglobin

Identifiers

PMID38388535
PMCPMC10883972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.